Pentwater Capital Management LP Calliditas Therapeutics Ab Transaction History

Pentwater Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$15.04 - $26.32 $691,840 - $1.21 Million	-46,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$21.03 - $33.19 $84,120 - $132,760	-4,000 Reduced 8.0%	46,000 $995,000
Q4 2020 Feb 16, 2021	SELL	$23.34 - $36.65 $258,700 - $406,228	-11,084 Reduced 18.15%	50,000 $1.68 Million
Q3 2020 Nov 16, 2020	SELL	$21.61 - $25.69 $106,234 - $126,292	-4,916 Reduced 7.45%	61,084 $1.47 Million
Q2 2020 Aug 14, 2020	BUY	$19.17 - $23.2 $1.27 Million - $1.53 Million	66,000 New	66,000 $1.53 Million

871K

1.5K

32.4K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.03B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Pentwater Capital Management LP with notifications on news.